Single User License
INR 135860
Site License
INR 271720
Corporate User License
INR 407580

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Chronic Kidney Disease (Chronic Renal Failure)-Pipeline Review, H1 2015

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Chronic Kidney Disease (Chronic Renal Failure)-Pipeline Review, H1 2015', provides an overview of the Chronic Kidney Disease (Chronic Renal Failure)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Chronic Kidney Disease (Chronic Renal Failure)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Chronic Kidney Disease (Chronic Renal Failure) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Chronic Kidney Disease (Chronic Renal Failure) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Chronic Kidney Disease (Chronic Renal Failure) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Chronic Kidney Disease (Chronic Renal Failure) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 8

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Chronic Kidney Disease (Chronic Renal Failure) Overview 11

Therapeutics Development 12

Pipeline Products for Chronic Kidney Disease (Chronic Renal Failure)-Overview 12

Pipeline Products for Chronic Kidney Disease (Chronic Renal Failure)-Comparative Analysis 13

Chronic Kidney Disease (Chronic Renal Failure)-Therapeutics under Development by Companies 14

Chronic Kidney Disease (Chronic Renal Failure)-Therapeutics under Investigation by Universities/Institutes 17

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline Products Glance 18

Late Stage Products 18

Clinical Stage Products 19

Early Stage Products 20

Unknown Stage Products 21

Chronic Kidney Disease (Chronic Renal Failure)-Products under Development by Companies 22

Chronic Kidney Disease (Chronic Renal Failure)-Products under Investigation by Universities/Institutes 25

Chronic Kidney Disease (Chronic Renal Failure)-Companies Involved in Therapeutics Development 26

Acceleron Pharma, Inc. 26

AFFiRiS AG 27

Angion Biomedica Corp. 28

Astellas Pharma Inc. 29

Bayer AG 30

Bio-inRen 31

Boryung Pharmaceutical Co., Ltd. 32

Celtic Biotech, Ltd. 33

Concert Pharmaceuticals, Inc. 34

Eli Lilly and Company 35

Evotec AG 36

Intercept Pharmaceuticals, Inc. 37

La Jolla Pharmaceutical Company 38

Multi Gene Vascular Systems Ltd 39

Nippon Zoki Pharmaceutical Co., Ltd. 40

OPKO Health, Inc. 41

Otsuka Holdings Co., Ltd. 42

Prolong Pharmaceuticals 43

ProMetic Life Sciences Inc. 44

Quark Pharmaceuticals, Inc. 45

Reata Pharmaceuticals, Inc. 46

Red Glead Discovery AB 47

Resverlogix Corp. 48

Sphaera Pharma Pvt. Ltd. 49

Stelic Institute & Co. 50

Toray Industries, Inc. 51

VBS Pharmaceuticals 52

Vicore Pharma AB 53

Chronic Kidney Disease (Chronic Renal Failure)-Therapeutics Assessment 54

Assessment by Monotherapy Products 54

Assessment by Target 55

Assessment by Mechanism of Action 57

Assessment by Route of Administration 59

Assessment by Molecule Type 61

Drug Profiles 63

ANG-3070-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

ANG-3557-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

ANG-4011-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

AS-2444697-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

ASP-6858-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

bardoxolone methyl-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

beraprost sodium SR-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

BR-05001-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

BRN-1889-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

C-21-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

calcifediol-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

CAR Peptide-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

Cardiotoxin-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

CTP-499-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

CXA-10-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

Drug for Kidney Diseases-Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

Drugs to Inhibit CYP24 for CKD and Pre-CKD-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

INT-767-Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

LJPC-101-Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

LY-3016859-Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

LY-3113593-Drug Profile 91

Product Description 91

Mechanism of Action 91

R&D Progress 91

MultiGeneGraft-Drug Profile 92

Product Description 92

Mechanism of Action 92

R&D Progress 92

NZ-419-Drug Profile 94

Product Description 94

Mechanism of Action 94

R&D Progress 94

PBI-4050-Drug Profile 96

Product Description 96

Mechanism of Action 96

R&D Progress 96

Peptide to Modulate GHSR for Chronic Kidney Disease-Drug Profile 97

Product Description 97

Mechanism of Action 97

R&D Progress 97

rivaroxaban-Drug Profile 98

Product Description 98

Mechanism of Action 98

R&D Progress 98

RNAi Oligonucleotide for Chronic Diseases-Drug Profile 103

Product Description 103

Mechanism of Action 103

R&D Progress 103

RVX-208-Drug Profile 104

Product Description 104

Mechanism of Action 104

R&D Progress 104

Sanguinate-Drug Profile 106

Product Description 106

Mechanism of Action 106

R&D Progress 106

Small Molecule to Inhibit Sodium-Phosphate Cotransport for CKD and Hypertension-Drug Profile 108

Product Description 108

Mechanism of Action 108

R&D Progress 108

Small Molecule to Inhibit Soluble Epoxide Hydrolase for Chronic Kidney Disease-Drug Profile 109

Product Description 109

Mechanism of Action 109

R&D Progress 109

Small Molecules for Chronic Kidney Disease-Drug Profile 110

Product Description 110

Mechanism of Action 110

R&D Progress 110

Small Molecules for Chronic Kidney Disease-Drug Profile 111

Product Description 111

Mechanism of Action 111

R&D Progress 111

sotatercept-Drug Profile 112

Product Description 112

Mechanism of Action 112

R&D Progress 112

SP-20103-Drug Profile 115

Product Description 115

Mechanism of Action 115

R&D Progress 115

SphK2 Program-Drug Profile 116

Product Description 116

Mechanism of Action 116

R&D Progress 116

SPR-494-Drug Profile 117

Product Description 117

Mechanism of Action 117

R&D Progress 117

STNM-310-Drug Profile 118

Product Description 118

Mechanism of Action 118

R&D Progress 118

tolvaptan-Drug Profile 119

Product Description 119

Mechanism of Action 119

R&D Progress 119

TRC-101-Drug Profile 121

Product Description 121

Mechanism of Action 121

R&D Progress 121

Vaccine for Chronic Kidney Disease-Drug Profile 122

Product Description 122

Mechanism of Action 122

R&D Progress 122

Vida-5-Drug Profile 123

Product Description 123

Mechanism of Action 123

R&D Progress 123

Chronic Kidney Disease (Chronic Renal Failure)-Recent Pipeline Updates 124

Chronic Kidney Disease (Chronic Renal Failure)-Dormant Projects 157

Chronic Kidney Disease (Chronic Renal Failure)-Discontinued Products 159

Chronic Kidney Disease (Chronic Renal Failure)-Product Development Milestones 160

Featured News & Press Releases 160

Apr 07, 2015: Resverlogix Receives Two Patents For RVX-208 In China 160

Mar 27, 2015: Phase 3 Data Supporting Rayaldee As a Treatment for Secondary Hyperparathyroidism in Chronic Kidney Disease to be Presented at NKF 2015 Spring Clinical Meetings 160

Mar 19, 2015: Prometic Successfully Completes Its Pbi-4050 Phase Ib In Patients With Chronic Kidney Disease 160

Mar 06, 2015: Phase 3 Data Supporting Rayaldee As a Treatment for Secondary Hyperparathyroidism in Chronic Kidney Disease to be Presented at ENDO 2015 Conference 161

Nov 13, 2014: Sotatercept Data from the Phase 2a Clinical Trial in Hemodialysis Patients Presented at the American Society of Nephrology Kidney Week 2014 161

Oct 22, 2014: Acceleron Announces Educational Webcast on Chronic Kidney Disease-Mineral and Bone Disorder 162

Aug 11, 2014: Rayaldee Phase 3 Trial Meets Primary Endpoints 162

Jul 02, 2014: Future Development Direction for Bardoxolone Methyl (RTA 402) 163

Jun 18, 2014: ProMetic Successfully Completes its PBI-4050 Phase I Clinical Trial 164

May 06, 2014: OPKO Completes Patient Enrollment in Third Phase 3 Trial of RAYALDEE 164

Appendix 166

Methodology 166

Coverage 166

Secondary Research 166

Primary Research 166

Expert Panel Validation 166

Contact Us 166

Disclaimer 167

List of Tables

Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H1 2015 12

Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure)-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 14

Number of Products under Development by Companies, H1 2015 (Contd..1) 15

Number of Products under Development by Companies, H1 2015 (Contd..2) 16

Number of Products under Investigation by Universities/Institutes, H1 2015 17

Comparative Analysis by Late Stage Development, H1 2015 18

Comparative Analysis by Clinical Stage Development, H1 2015 19

Comparative Analysis by Early Stage Development, H1 2015 20

Comparative Analysis by Unknown Stage Development, H1 2015 21

Products under Development by Companies, H1 2015 22

Products under Development by Companies, H1 2015 (Contd..1) 23

Products under Development by Companies, H1 2015 (Contd..2) 24

Products under Investigation by Universities/Institutes, H1 2015 25

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Acceleron Pharma, Inc., H1 2015 26

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by AFFiRiS AG, H1 2015 27

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Angion Biomedica Corp., H1 2015 28

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Astellas Pharma Inc., H1 2015 29

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Bayer AG, H1 2015 30

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Bio-inRen, H1 2015 31

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Boryung Pharmaceutical Co., Ltd., H1 2015 32

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Celtic Biotech, Ltd., H1 2015 33

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Concert Pharmaceuticals, Inc., H1 2015 34

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Eli Lilly and Company, H1 2015 35

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Evotec AG, H1 2015 36

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Intercept Pharmaceuticals, Inc., H1 2015 37

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by La Jolla Pharmaceutical Company, H1 2015 38

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Multi Gene Vascular Systems Ltd, H1 2015 39

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Nippon Zoki Pharmaceutical Co., Ltd., H1 2015 40

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by OPKO Health, Inc., H1 2015 41

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Otsuka Holdings Co., Ltd., H1 2015 42

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Prolong Pharmaceuticals, H1 2015 43

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by ProMetic Life Sciences Inc., H1 2015 44

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Quark Pharmaceuticals, Inc., H1 2015 45

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Reata Pharmaceuticals, Inc., H1 2015 46

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Red Glead Discovery AB, H1 2015 47

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Resverlogix Corp., H1 2015 48

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Sphaera Pharma Pvt. Ltd., H1 2015 49

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Stelic Institute & Co., H1 2015 50

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Toray Industries, Inc., H1 2015 51

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by VBS Pharmaceuticals, H1 2015 52

Chronic Kidney Disease (Chronic Renal Failure)-Pipeline by Vicore Pharma AB, H1 2015 53

Assessment by Monotherapy Products, H1 2015 54

Number of Products by Stage and Target, H1 2015 56

Number of Products by Stage and Mechanism of Action, H1 2015 58

Number of Products by Stage and Route of Administration, H1 2015 60

Number of Products by Stage and Molecule Type, H1 2015 62

Chronic Kidney Disease (Chronic Renal Failure) Therapeutics-Recent Pipeline Updates, H1 2015 124

Chronic Kidney Disease (Chronic Renal Failure)-Dormant Projects, H1 2015 157

Chronic Kidney Disease (Chronic Renal Failure)-Dormant Projects (Contd..1), H1 2015 158

Chronic Kidney Disease (Chronic Renal Failure)-Discontinued Products, H1 2015 159

List of Figures

Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H1 2015 12

Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure)-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 14

Comparative Analysis by Clinical Stage Development, H1 2015 19

Comparative Analysis by Early Stage Products, H1 2015 20

Assessment by Monotherapy Products, H1 2015 54

Number of Products by Top 10 Targets, H1 2015 55

Number of Products by Stage and Top 10 Targets, H1 2015 55

Number of Products by Top 10 Mechanism of Actions, H1 2015 57

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 57

Number of Products by Top 10 Routes of Administration, H1 2015 59

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 60

Number of Products by Top 10 Molecule Types, H1 2015 61

Number of Products by Stage and Top 10 Molecule Types, H1 2015 62

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Acceleron Pharma, Inc.

AFFiRiS AG

Angion Biomedica Corp.

Astellas Pharma Inc.

Bayer AG

Bio-inRen

Boryung Pharmaceutical Co., Ltd.

Celtic Biotech, Ltd.

Concert Pharmaceuticals, Inc.

Eli Lilly and Company

Evotec AG

Intercept Pharmaceuticals, Inc.

La Jolla Pharmaceutical Company

Multi Gene Vascular Systems Ltd

Nippon Zoki Pharmaceutical Co., Ltd.

OPKO Health, Inc.

Otsuka Holdings Co., Ltd.

Prolong Pharmaceuticals

ProMetic Life Sciences Inc.

Quark Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc.

Red Glead Discovery AB

Resverlogix Corp.

Sphaera Pharma Pvt. Ltd.

Stelic Institute & Co.

Toray Industries, Inc.

VBS Pharmaceuticals

Vicore Pharma AB

Chronic Kidney Disease (Chronic Renal Failure) Therapeutic Products under Development, Key Players in Chronic Kidney Disease (Chronic Renal Failure) Therapeutics, Chronic Kidney Disease (Chronic Renal Failure) Pipeline Overview, Chronic Kidney Disease (Chronic Renal Failure) Pipeline, Chronic Kidney Disease (Chronic Renal Failure) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com